Faculty of Kinesiology, Roger Jackson Centre for Health and Wellness Research
Calgary, Alberta, T2N 1N4, Canada
NCT Number: NCT00522353
The purpose of this study is to determine if oligofructose supplementation promotes weight loss in overweight and obese adults.
Looking for future studies?
Notify Me20 year–70 year
All sexes
Interventional
Not applicable
Calgary, Alberta, T2N 1N4, Canada
Obesity is a primary health concern for many western countries as it is linked to several chronic diseases as well as, large health care costs. Although obesity is a multifactorial disease, it is known that levels of satiety hormones including glucagon like peptide-1 (GLP-1) and peptide YY (PYY) are reduced in obesity. The ability of prebiotic fiber to promote weight loss through the production of satiety hormones has been tested previously using rodents. Here it was found that prebiotic supplementation resulted in a decreased energy intake, higher GLP-1 levels in the plasma and increased proglucagon mRNA levels in the gut. This study will address the important question of whether prebiotic fiber supplementation is effective in reducing body weight in overweight or obese human subjects.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
21 grams per day in distributed over 3 doses per day for 3 months
Other names: Raftilose P95
7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
Other names: Maltrin M100
Time frame: 3 months
Time frame: 3 months
University of Calgary
Other
Effect of Oligofructose Versus Placebo on Body Weight and Satiety Hormone Secretion in Overweight and Obese Adults.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00687115
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT05184361
Body Weight, Body Weight Changes
Cruz Quebrada, Lisbon District, Portugal
View Trial DetailsNCT05424081
Body Weight, Body Weight Changes
Palo Alto, California, United States
View Trial DetailsNCT05104450
Apnea, Behavior
Seattle, Washington, United States
View Trial Details